Alejandra Castello Guillen

Ms. Alejandra Castello Guillen

Valencia Catholic University Saint Vincent Martyr, Valencia, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Alejandra Castello GuillenAlejandra Castello Guillen
Alejandra Castello Guillen
MRMarta Garrido Reig
Marta Garrido Reig
JLJordi Caplliure Llopis
Jordi Caplliure Llopis
MVMARÍA JESÚS VEGA-BELLO
MARÍA JESÚS VEGA-BELLO
CACelia Almela
Celia Almela
Jose Enrique de la Rubia Ortí OrtíJose Enrique de la Rubia Ortí Ortí
Jose Enrique de la Rubia Ortí Ortí
Background/Objectives: The main neurodegenerative diseases (NDs) - Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) - represent a growing global health burden with no available disease-modifying therapies. Curcumin, a polyphenol from Curcuma longa, is a promising candidate owing to its pleiotropic antioxidant, anti-inflammatory, and neuroprotective profile, but its oral bioavailability (<1%) and blood-brain barrier (BBB) penetration (<0.1%) severely limit its clinical application. The objective of this work was to critically examine the therapeutic potential of curcumin in NDs, focusing on advanced drug delivery systems (DDS) designed to overcome its pharmacokinetic barriers. Methods: Narrative, non-systematic review of PubMed/MEDLINE, Scopus, and Web of Science, structured around five areas: molecular mechanisms, pharmacokinetic barriers, evolution of DDS, disease-specific applications, and translational limitations. Results: Curcumin exhibits neuroprotective activity in preclinical models of the four NDs analysed, acting on six interconnected mechanisms and the gut-brain axis. Four generations of DDS have been developed, from phytosomes and clinically used lipid dispersions (Meriva®, BCM-95®, Longvida®, Theracurmin®) to fourth-generation systems (biomimetic nanoparticles, MOFs, microneedles, 3D scaffolds, hydrogels, carbon dots) that substantially increase bioavailability in preclinical studies. Combination strategies, such as curcumin with resveratrol and dutasteride, show preliminary clinical signals in ALS. However, clinical translation remains limited: over 80% of positive animal findings have not been replicated in humans, formulation characterization is frequently incomplete, and most trials lack CNS-exposure biomarkers. Conclusions: DDS are essential to unlock curcumin’s therapeutic potential in neurology, but its clinical translation requires phase II/III trials with well-characterized formulations, cerebrospinal fluid exposure biomarkers, and adaptive designs.

Verified
Journal Article
Open access
PDF file
Jose Enrique de la Rubia Ortí OrtíJose Enrique de la Rubia Ortí Ortí
Jose Enrique de la Rubia Ortí Ortí
ASAlba Roig Soriano
Alba Roig Soriano
SJSandra Carrera Juliá
Sandra Carrera Juliá
Alejandra Castello GuillenAlejandra Castello Guillen
Alejandra Castello Guillen
Marisa Rodrigues MachadoMarisa Rodrigues Machado
Marisa Rodrigues Machado
María BenllochMaría Benlloch
María Benlloch
Multiple sclerosis (MS) is characterized by progressive mitochondrial dysfunction affecting complexes I, III, and IV of the electron transport chain, contributing to axonal energy failure and neurodegeneration. This review examines the potential of combining β-hydroxybutyrate (βHB), epigallocatechin-3-gallate (EGCG), and ellagic acid (EA) as a multi-target therapeutic strategy to restore mitochondrial function in patients with MS. Experimental and clinical studies demonstrate that each compound exerts complementary mechanisms. Ketone bodies provide an alternative energy substrate and restore complex I activity via sirtuin-dependent pathways. EGCG acts predominantly at the peripheral level by reducing systemic inflammation and oxidative stress. EA-derived urolithins effectively cross the blood–brain barrier to directly enhance mitochondrial biogenesis and respiratory chain function in the central nervous system. Clinical trials have reported improvements in fatigue, cognition, mood, and muscle function following supplementation with these compounds. The convergence of their actions on energy restoration, reactive oxygen species reduction, and epigenetic modulation of protective pathways suggests their synergistic potential. Optimized delivery strategies, including exogenous ketone salts, liposomal EGCG, and microencapsulated EA, may overcome bioavailability limitations and interindividual variability in the gut microbiota metabolism.

6 September 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Alejandra Castello GuillenAlejandra Castello Guillen
Alejandra Castello Guillen
MRMarta Garrido Reig
Marta Garrido Reig
JLJordi Caplliure Llopis
Jordi Caplliure Llopis
MVMARÍA JESÚS VEGA-BELLO
MARÍA JESÚS VEGA-BELLO
CACelia Almela
Celia Almela
Jose Enrique de la Rubia Ortí OrtíJose Enrique de la Rubia Ortí Ortí
Jose Enrique de la Rubia Ortí Ortí
Background and Objectives: The main neurodegenerative diseases (NDs)—Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS)—represent a growing global health burden with no available disease-modifying therapies. Curcumin, a polyphenol from Curcuma longa, is a promising candidate owing to its pleiotropic antioxidant, anti-inflammatory, and neuroprotective profile observed mainly in preclinical models, but the poor oral bioavailability (<1%) and negligible BBB penetration (<0.1%) have substantially limited curcumin’s clinical translation. The objective of this work was to critically examine the therapeutic potential of curcumin in NDs, focusing on advanced drug delivery systems (DDSs) designed to overcome its pharmacokinetic barriers. Methods: This is a narrative, non-systematic review of PubMed/MEDLINE, Scopus, and Web of Science. The review is organized around five complementary thematic areas selected to span the full translational pipeline of curcumin in neurodegeneration, from mechanistic rationale to clinical applicability: (1) molecular mechanisms, addressing the pleiotropic activities that justify therapeutic interest; (2) pharmacokinetic barriers, the principal obstacle to clinical translation; (3) the evolution of drug delivery systems (DDSs), documenting the technological strategies developed to overcome these barriers; (4) disease-specific applications, evaluating the available evidence across the four main NDs; and (5) translational limitations, identifying the methodological and regulatory gaps that must be closed to enable clinical implementation. Results: Curcumin exhibits neuroprotective activity in preclinical models of the four NDs analysed, acting on six interconnected mechanisms and the gut–brain axis. Four generations of DDSs have been developed, from phytosomes and clinically used lipid dispersions (Meriva®, BCM-95®, Longvida®, and Theracurmin®) to fourth-generation systems (biomimetic nanoparticles, MOFs, microneedles, 3D scaffolds, hydrogels, and carbon dots) that substantially increase the bioavailability in preclinical studies. Combination strategies, such as curcumin with resveratrol and dutasteride, show preliminary clinical signals in ALS. However, clinical translation remains limited: over 80% of positive animal findings have not been replicated in humans, formulation characterization is frequently incomplete, and most trials lack CNS-exposure biomarkers. Importantly, most of the reported bioavailability claims are based on total curcumin measurements (parent aglycone plus its inactive Phase II conjugates) rather than the active aglycone alone, a methodological limitation that should be considered when interpreting the magnitude of the bioavailability improvements reported for novel formulations. Conclusions: Curcumin exhibits pleiotropic neuroprotective activity in preclinical models of AD, PD, MS, and ALS, mediated by interconnected antioxidant, anti-inflammatory, anti-amyloidogenic, mitochondrial, and gut–brain axis mechanisms. However, its poor systemic bioavailability (<1%), minimal blood–brain barrier penetration, and extensive first-pass metabolism have limited clinical translation. Advanced drug delivery systems (including lipid-based carriers (liposomes, solid lipid nanoparticles, and nanostructured lipid carriers), polymeric nanoparticles (PLGA and chitosan), and bioinspired vesicles (exosomes)) are essential in order to overcome these barriers. Nevertheless, the formulation heterogeneity, limited long-term safety data, and reliance on preclinical models remain major obstacles; a definitive clinical translation will therefore require well-characterized formulations validated in phase II/III trials with cerebrospinal fluid exposure biomarkers, the pharmacokinetic monitoring of active aglycone (rather than total curcumin including inactive conjugates), and adaptive trial designs in neurological populations.